4.8 Article

A small-molecule inhibitor of skeletal muscle myosin II

Journal

NATURE CELL BIOLOGY
Volume 4, Issue 1, Pages 83-88

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/ncb734

Keywords

-

Categories

Funding

  1. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL015835] Funding Source: NIH RePORTER
  2. NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023928, P01GM062566] Funding Source: NIH RePORTER
  3. NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017620] Funding Source: NIH RePORTER
  4. NHLBI NIH HHS [HL15835] Funding Source: Medline
  5. NIGMS NIH HHS [GM23928, GM62566] Funding Source: Medline
  6. NINDS NIH HHS [NS17620] Funding Source: Medline

Ask authors/readers for more resources

We screened a small-molecule library for inhibitors of rabbit muscle myosin II subfragment 1 (S1) actin-stimulated ATPase activity. The best inhibitor, N-benzyl-p-toluene sulphonamide (BTS), an aryl sulphonamide, inhibited the Ca2+-stimulated S1 ATPase, and reversibly blocked gliding motility. Although BTS does not compete for the nucleotide-binding site of myosin, it weakens myosin's interaction with F-actin. BTS reversibly suppressed force production in skinned skeletal muscle fibres from rabbit and frog skin at micromolar concentrations. BTS suppressed twitch production of intact frog fibres with minimum alteration of Ca2+ metabolism. BTS is remarkably specific, as it was much less effective in suppressing contraction in rat myocardial or rabbit slow-twitch muscle, and did not inhibit platelet myosin II. The isolation of BTS and the recently discovered Eg5 kinesin inhibitor, monastrol(1), suggests that motor proteins may be potential targets for therapeutic applications.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available